TAYSHA GENE THERAPIES INC. - COMMON STOCK

Taysha Gene Therapies Reports Initial Clinical Data from First Adult Rett Syndrome Patient Dosed in REVEAL Phase 1/2 Trial and Provides Corporate Update with Second Quarter 2023 Financial Results

14 Aug 2023 06:02:00 By Nasdaq GlobeNewswire

Taysha Gene Therapies Announces $150 Million Private Placement Financing

14 Aug 2023 06:00:00 By Nasdaq GlobeNewswire

Taysha Gene Therapies Announces Positive Recommendation from Independent Data Monitoring Committee of REVEAL Phase 1/2 Trial in Rett Syndrome

31 Jul 2023 07:00:00 By Nasdaq GlobeNewswire

Taysha Gene Therapies Provides Clinical Updates for Investigational Programs TSHA-120 in Giant Axonal Neuropathy (GAN) and TSHA-102 in Rett Syndrome at R&D Day

28 Jun 2023 07:00:01 By Nasdaq GlobeNewswire

Taysha Gene Therapies to Host Virtual R&D Day on Lead Clinical Investigational Programs TSHA-120 in Giant Axonal Neuropathy (GAN) and TSHA-102 in Rett Syndrome

15 Jun 2023 07:00:00 By Nasdaq GlobeNewswire

Taysha Gene Therapies Announces First Patient Dosed with TSHA-102 in the REVEAL Phase 1/2 Trial Under Investigation for the Treatment of Rett Syndrome

05 Jun 2023 07:00:00 By Nasdaq GlobeNewswire

Taysha Gene Therapies Presents Preclinical Data on TSHA-102 for Rett Syndrome Demonstrating Cellular Regulation of MeCP2 Expression in Key Mouse Models at the American Society of Gene and Cell Therapy 26th Annual Meeting

19 May 2023 07:00:00 By Nasdaq GlobeNewswire

Taysha Gene Therapies Reports First Quarter 2023 Financial Results and Provides Corporate Update

11 May 2023 15:01:01 By Nasdaq GlobeNewswire

Taysha Gene Therapies to Release First Quarter 2023 Financial Results and Host Conference Call and Webcast on May 11

04 May 2023 07:00:00 By Nasdaq GlobeNewswire

Taysha Gene Therapies Announces Presentation on New Preclinical Data for TSHA-102 in Rett Syndrome at Upcoming American Society of Gene and Cell Therapy 26th Annual Meeting

27 Apr 2023 15:52:53 By Nasdaq GlobeNewswire

Taysha Gene Therapies Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

28 Mar 2023 15:01:00 By Nasdaq GlobeNewswire

Taysha Gene Therapies to Release Fourth Quarter and Full-Year 2022 Financial Results and Host Conference Call and Webcast on March 28

15 Mar 2023 15:01:00 By Nasdaq GlobeNewswire

Taysha Gene Therapies Provides Update on TSHA-120 Program in Giant Axonal Neuropathy and a 2023 Corporate Outlook

31 Jan 2023 15:01:00 By Nasdaq GlobeNewswire

Taysha Gene Therapies Announces Executive Leadership Changes

16 Dec 2022 17:18:58 By Nasdaq GlobeNewswire

Taysha Gene Therapies to Participate in JMP Securities Hematology and Oncology Summit

29 Nov 2022 15:01:00 By Nasdaq GlobeNewswire

Taysha Gene Therapies Reports Third Quarter 2022 Financial Results and Provides Corporate Update

08 Nov 2022 06:00:02 By Nasdaq GlobeNewswire

Taysha Gene Therapies to Release Third Quarter 2022 Financial Results and Host Conference Call and Webcast on November 8

02 Nov 2022 06:00:01 By Nasdaq GlobeNewswire

Taysha Announces Pricing of Public Offering of Common Stock

26 Oct 2022 18:54:50 By Nasdaq GlobeNewswire

Taysha Gene Therapies Announces Proposed Public Offering of Common Stock

25 Oct 2022 15:01:00 By Nasdaq GlobeNewswire

Taysha Gene Therapies to Host Conference Call to Discuss Astellas Pharma’s Strategic Investment to Support the Development of Taysha’s AAV-based Gene Therapy Programs

24 Oct 2022 18:35:00 By Nasdaq GlobeNewswire